Form 4: Janux Therapeutics Executive Sells Shares for Tax

Chief Corporate & Business Development Officer Janeen Noel Doyle sold 4,059 shares of Janux Therapeutics to cover tax obligations.

Summary

• Janeen Noel Doyle, Chief Corporate & Business Development Officer at Janux Therapeutics, Inc. (JANX), sold 4,059 shares of common stock.
• The transaction occurred on June 2, 2026, at a weighted average price of $14.029 per share.
• The sale was executed automatically to satisfy tax withholding obligations related to the vesting of restricted stock units.
• Following the transaction, the reporting person retains beneficial ownership of 75,941 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative and mandatory for tax compliance.

Positives

• The sale was a non-discretionary transaction triggered by tax withholding requirements, rather than a voluntary divestment of shares.

Negatives

• Reduction in the executive's direct equity stake in the company.

Risks

• None identified; this is a routine administrative transaction.

Future Outlook

Not applicable; this is a retrospective disclosure of a completed transaction.

Industry Context

StockSavvy.ai notes that automatic sell-to-cover transactions are standard practice in the biotechnology sector for executives receiving equity-based compensation, and they generally do not signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for handling tax liabilities associated with RSU vesting.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was non-discretionary.

Key Dates

Keywords

Janux Therapeutics, JANX, Insider Trading, Form 4, Biotech, Equity Compensation